Keywords: دوز محدود کننده سمیت; Dose-limiting toxicity; Recommended phase II dose; Maximum tolerated dose; Dose-finding clinical trials; Early drug development; Paediatrics; Oncology;
مقالات ISI دوز محدود کننده سمیت (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: دوز محدود کننده سمیت; autophagy; FEV1; lymphangioleiomyomatosis; sirolimus; VEGF-D; 6-MWD; 6-min walk distance; AML; angiomyolipoma; Dlco; diffusion coefficient for carbon monoxide; DLT; dose-limiting toxicity; LAM; lymphangioleiomyomatosis; MTD; maximal tolerated dose; NCI; N
Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer
Keywords: دوز محدود کننده سمیت; BID; twice daily; CARBO-ETOP; carboplatin-etoposide therapy; CDK; cyclin-dependent kinase; CI; confidence interval; CIS-ETOP; cisplatin-etoposide therapy; DCR; disease control rate; DLT; dose-limiting toxicity; DoR; duration of response; ED-SCLC; extensiv
Original articleA phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib
Keywords: دوز محدود کننده سمیت; AE; adverse events; Afa; afatinib; AR; acquired resistance; AUC; area under curve; CR; complete response; CTCAE; Common Terminology Criteria for Adverse Events; CTP; clinical trial protocol; DLT; dose-limiting toxicity; ECOG; Eastern Cooperative Oncology
EUS-guided paclitaxel injection as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation before surgery for localized or locoregional esophageal cancer: a multicenter prospective randomized trial
Keywords: دوز محدود کننده سمیت; 5-FU; 5-fluorouracil; AE; adverse event; CI; confidence interval; CR; complete response; CRT; chemoradiotherapy; DLT; dose-limiting toxicity; ECOG; Eastern Cooperative Oncology Group; KPS; Karnofsky Performance Status; mITT; modified intention to treat; m
A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient population
Keywords: دوز محدود کننده سمیت; CAR-T; chimeric antigen receptor T-cells; CR; complete response; DLBCL; diffuse large B-cell lymphoma; DLT; dose-limiting toxicity; MCL; mantle cell lymphoma; MTD; maximum tolerated dose; NHL; non-Hodgkin lymphoma; Adaptive randomization; Bayesian adaptiv
Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study
Keywords: دوز محدود کننده سمیت; BBB; blood-brain barrier; BCRP; breast cancer-resistant protein; CIs; confidence intervals; CSF; cerebrospinal fluid; CT; computed tomography; DCR; disease control rates; DLT; dose-limiting toxicity; ECOG; Eastern Cooperative Oncology Group; EC-PFS; ext
Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer
Keywords: دوز محدود کننده سمیت; HER; human epidermal growth factor receptor; NSCLC; non-small cell lung cancer; DLT; dose-limiting toxicity; MTD; maximum tolerated dose; EGFR-TKI; epidermal growth factor receptor-tyrosine kinase inhibitor; RECIST; response evaluation criteria in solid t
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey
Keywords: دوز محدود کننده سمیت; Dose-limiting toxicity; Assessment period; Experts; Dose intensity; Phase 1; Recommended phase 2 dose
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia
Keywords: دوز محدود کننده سمیت; AML; acute myeloid leukemia; DLT; dose-limiting toxicity; DSMC; Data Safety Monitoring Committee; EMSA; electrophoretic mobility shift assay; FACS; fluorescence-activated cell sorting; iKBa; inhibitor of NF-kB; LSC; leukemic stem cell; MDS; myelodysplasti
Oral Ketamine for Children with Chronic Pain: A Pilot Phase 1 Study
Keywords: دوز محدود کننده سمیت; AUC; Area under the plasma concentration-time curve; CRM; Continual reassessment method; CYP; Cytochrome P450; DLT; Dose-limiting toxicity; DN4; Douleur Neuropathique 4; NOS; Not otherwise specified; NRS; Numerical rating scale;
Transcatheter Arterial Chemoembolization Using Cisplatin Powder Mixed with Degradable Starch Microspheres for Colorectal Liver Metastases after FOLFOX Failure: Results of a Phase I/II Study
Keywords: دوز محدود کننده سمیت; ALT; alanine aminotransferase; AST; aspartate aminotransferase; CEA; carcinoembryonic antigen; CI; confidence interval; DLT; dose-limiting toxicity; DSM; degradable starch microspheres; 5-FU; 5-fluorouracil; FOLFIRI; 5-FU, leucovorin plus irinotecan; FOLF
Phase I/II Study of Radiologic Hepatic Arterial Infusion of Fluorouracil Plus Systemic Irinotecan for Unresectable Hepatic Metastases from Colorectal Cancer: Japan Clinical Oncology Group Trial 0208-DI
Keywords: دوز محدود کننده سمیت; AE; adverse event; CRC; colorectal cancer; DLT; dose-limiting toxicity; DSA; digital subtraction angiography; HAIC; hepatic arterial infusion chemotherapy; MTD; maximum tolerated dose; OS; overall survival; RD; recommended dose; WBC; white blood cell;
Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer
Keywords: دوز محدود کننده سمیت; Dose-limiting toxicity; Erlotinib; Everolimus; Non–small-cell lung cancer; Phase I
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer
Keywords: دوز محدود کننده سمیت; DFS; disease-free survival; DLT; dose-limiting toxicity; 5-FU; 5-fluorouracil; OS; overall survival; pCR; pathologic complete response; PU; particle units; RT; radiation therapy; TE; thrombotic/thromboembolic event; TNF-α; tumor necrosis factor-α;
Phase I Study of Heat-Deployed Liposomal Doxorubicin during Radiofrequency Ablation for Hepatic Malignancies
Keywords: دوز محدود کننده سمیت; ALT; alanine aminotransferase; AST; aspartate aminotransferase; AUC; area under the plasma concentration-time curve; AUC0-â; area under the plasma concentration-time curve from time 0 to infinity; DLT; dose-limiting toxicity; LTLD; lyso-thermosens
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
Keywords: دوز محدود کننده سمیت; DLT; dose-limiting toxicity; ET; essential thrombocythemia; MF; myelofibrosis; MPN; myeloproliferative neoplasm; MTD; maximum tolerated dose; PMF; primary MF; PV; polycythemia vera;
Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer
Keywords: دوز محدود کننده سمیت; Dose-limiting toxicity; Dose-painting-by-numbers; Adaptive IMRT; Head and neck cancer; 18F-FDG-PET;
Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: A review of the literature
Keywords: دوز محدود کننده سمیت; Phase I trials; Molecularly targeted agents; Dose-limiting toxicity; Definition; NCI CTCAE; Duration of toxicity; Reversibility;
Concurrent Chemoradiation Therapy With Docetaxel/Cisplatin Followed by Docetaxel Consolidation Therapy in Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer: Results of a Phase I Study
Keywords: دوز محدود کننده سمیت; Dose-limiting toxicity; Forced expiratory volume; Hemoglobin; Maximum tolerated dose
Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis
Keywords: دوز محدود کننده سمیت; AE; adverse event; AUC0-24; area under the curve 0 to 24 hours; CE(P)C; circulating endothelial (progenitor) cells; Cmax; maximum observed plasma concentration; CTCAE; Common Terminology Criteria for Adverse Events; DLT; dose-limiting toxicity; EGFR; epid
Reduced dose-limiting toxicity of intraperitoneal mitoxantrone chemotherapy using cardiolipin-based anionic liposomes
Keywords: دوز محدود کننده سمیت; Intraperitoneal chemotherapy; Mitoxanthrone; Cardiolipin liposomes; Dose-limiting toxicity; Prolonged retention
Phase I and Pharmacologic Study of Weekly Bolus Topotecan for Advanced Non-Small-Cell Lung Cancer
Keywords: دوز محدود کننده سمیت; Dose-limiting toxicity; Maximum tolerated dose; N-desmethyl topotecan; Pharmacokinetics;
Infusional 5-Fluorouracil and ZD1839 (Gefitinib-Iressa) in Combination With Preoperative Radiotherapy in Patients With Locally Advanced Rectal Cancer: A Phase I and II Trial (1839IL/0092)
Keywords: دوز محدود کننده سمیت; Gefitinib; Preoperative; Chemoradiation; Rectal cancer; TRG; Dose-limiting toxicity;
Continuous-Infusion Vinorelbine for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Phase I/II Study
Keywords: دوز محدود کننده سمیت; Dose-limiting toxicity; First-line therapy; Maximum tolerated dose; Mucositis; Neutropenia;
Safety and Tolerability of PCK3145, a Synthetic Peptide Derived from Prostate Secretory Protein 94 (PSP94) in Metastatic Hormone-Refractory Prostate Cancer
Keywords: دوز محدود کننده سمیت; Angiogenesis; Dose-limiting toxicity; Invasiveness; Matrix metalloproteinase-9;